6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01566695 [Disease Site] Myelodysplastic/Myleofroliferative Syndromes [Description] 
A Phase III, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-Risk Myelodysplastic Syndromes
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description